🔴 Chimeric Therapeutics is trading 13.33% down today after CHM-2101 trial enrolment and dosing stopped

Chimeric Therapeutics is trading 13.33% down at A$0.01 after enrolment and dosing stopped in the CHM-2101 Phase 1 trial.

• The August 19, 2026 announcement said the independent Safety Monitoring Committee deemed Dose Level 3 unsafe after a second patient experienced dose-limiting toxicities.
• The company will not progress CHM-2101 in its current form.
• The decline follows substantial weakness on August 24, amid concern about development risk and funding despite broader biotech-sector strength. Trading-volume data was not provided.